Residency · Residency · Hematology Thrombosis

Hemolytic Anemia - Classification and Workup

Introduction

Hemolytic anemia results from accelerated red blood cell destruction, with the RBC lifespan shortened below its normal span of approximately 120 days. The bone marrow possesses a remarkable compensatory capacity, capable of increasing erythropoietic output by six- to eight-fold above baseline. Anemia develops only when the rate of red cell destruction exceeds this maximal production capacity. A systematic, methodical approach to the classification and workup of hemolytic anemia is essential for arriving at the correct diagnosis and guiding appropriate therapy, as the differential diagnosis is broad and the therapeutic implications of specific etiologies are vastly different.

Pathophysiology of Hemolysis

Intravascular vs. Extravascular Hemolysis

The site of red blood cell destruction provides the first fundamental division in understanding hemolytic anemias. Extravascular hemolysis, which accounts for the majority of hemolytic conditions, involves the destruction of red blood cells by reticuloendothelial macrophages, primarily in the spleen and liver. Red cells that are opsonized with IgG or C3b, or that are morphologically abnormal and unable to navigate the narrow splenic sinusoidal passages, are trapped in the splenic cords and phagocytosed. The laboratory signature of extravascular hemolysis includes elevated indirect bilirubin (from heme catabolism), modestly elevated LDH, decreased haptoglobin (which binds free hemoglobin released from any hemolytic process), and reticulocytosis reflecting the compensatory marrow response. Haptoglobin may remain within the normal range in mild extravascular hemolysis.

Intravascular hemolysis involves red cell lysis directly within the vasculature, releasing free hemoglobin into the plasma. This occurs through complement-mediated lysis via the membrane attack complex (MAC), mechanical shear forces, or direct toxic injury. The laboratory signature is more dramatic and includes a markedly decreased or absent haptoglobin, hemoglobinemia (visible as pink or red discoloration of the plasma), hemoglobinuria (dark or cola-colored urine), hemosiderinuria (detectable days after the acute event as renal tubular cells slough), elevated plasma-free hemoglobin, and often markedly elevated LDH. Free hemoglobin in the plasma first binds haptoglobin, which is cleared rapidly by CD163-positive macrophages. When haptoglobin is exhausted, excess free hemoglobin is oxidized to methemoglobin, which binds albumin to form methemalbumin. Free hemoglobin that is filtered by the kidneys produces hemoglobinuria and, over subsequent days, hemosiderinuria as iron-laden tubular epithelial cells are shed.

Key Laboratory Markers

The distinction between intravascular and extravascular hemolysis is primarily made on the basis of laboratory findings. In intravascular hemolysis, haptoglobin is typically absent (below 10 mg/dL), LDH is markedly elevated, plasma free hemoglobin is elevated, hemoglobinuria is present, and urine hemosiderin is positive (appearing days after the event). In extravascular hemolysis, haptoglobin is low to absent, LDH is mildly to moderately elevated, plasma free hemoglobin is normal, and hemoglobinuria and hemosiderinuria are absent. Both forms share elevated indirect bilirubin and reticulocytosis. Schistocytes on the peripheral smear may be present in intravascular hemolysis from mechanical causes but are not universally seen.

Classification Framework

Intrinsic (Corpuscular) Defects

Intrinsic or corpuscular defects are those arising from abnormalities within the red blood cell itself. Membrane disorders include hereditary spherocytosis (HS), the most common hereditary hemolytic anemia in Northern Europeans, hereditary elliptocytosis (HE), hereditary pyropoikilocytosis (HPP), and Southeast Asian ovalocytosis. Enzyme deficiencies include glucose-6-phosphate dehydrogenase (G6PD) deficiency, the most common enzymopathy worldwide, pyruvate kinase (PK) deficiency, the most common glycolytic enzyme defect causing hemolysis, and pyrimidine 5'-nucleotidase deficiency. Hemoglobinopathies include sickle cell disease, unstable hemoglobin variants, and the thalassemia syndromes, which are partially hemolytic. Paroxysmal nocturnal hemoglobinuria (PNH) occupies a unique position as the only acquired intrinsic defect, resulting from a somatic mutation in the PIGA gene leading to deficiency of GPI-anchored complement regulatory proteins.

Extrinsic Causes

Extrinsic causes of hemolysis originate outside the red blood cell. Immune-mediated causes include autoimmune hemolytic anemia (warm AIHA, cold agglutinin disease, and mixed types), alloimmune hemolysis (transfusion reactions and hemolytic disease of the newborn), and drug-induced immune hemolytic anemia. Mechanical and microangiopathic causes include thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), disseminated intravascular coagulation (DIC), HELLP syndrome, mechanical heart valves, extracorporeal membrane oxygenation (ECMO), and march hemoglobinuria. Infectious causes include malaria, babesiosis, Clostridium perfringens sepsis, and bartonellosis. Toxic and chemical causes include copper (as in Wilson disease), lead, spider and snake venoms, and arsine gas. Hypersplenism causes hemolysis through sequestration and destruction in an enlarged spleen, while osmotic causes include freshwater drowning and inadvertent infusion of hypotonic intravenous solutions.

<image>A comprehensive classification diagram of hemolytic anemias organized as a large branching tree. The first branch divides into Intrinsic (Corpuscular) and Extrinsic causes. Under Intrinsic, show three main categories: Membrane Defects (hereditary spherocytosis, elliptocytosis, PNH), Enzyme Defects (G6PD deficiency, pyruvate kinase deficiency), and Hemoglobin Defects (sickle cell, unstable hemoglobins, thalassemia). Under Extrinsic, show: Immune-Mediated (warm AIHA, cold agglutinin, alloimmune, drug-induced), Mechanical (TTP, HUS, DIC, prosthetic valves), Infectious (malaria, babesiosis, Clostridium), and Other (toxins, hypersplenism). For each final category, include a small icon showing the characteristic peripheral smear finding (spherocytes, elliptocytes, sickle cells, schistocytes, bite cells). Use color coding to distinguish hereditary (blue) from acquired (orange) causes. Medical textbook style.</image>

Systematic Diagnostic Workup

Step 1: Confirm Hemolysis

The first step is to confirm that hemolysis is actually occurring. The absolute reticulocyte count should exceed 100,000 per microliter, or the reticulocyte percentage should be above 2%. The reticulocyte production index (RPI), which corrects for the degree of anemia and for the prolonged maturation time of shift reticulocytes released prematurely from the marrow, should exceed 2 to indicate an adequate marrow response to hemolysis. LDH is elevated, with isoenzymes 1 and 2 predominating (reflecting red cell origin). Indirect bilirubin is elevated from heme degradation. Haptoglobin is decreased, with levels below 25 mg/dL being highly suggestive and levels below 10 mg/dL being virtually diagnostic of hemolysis. However, haptoglobin is an acute phase reactant and may be falsely normal when hemolysis coincides with an inflammatory state. Additionally, congenital ahaptoglobinemia affects approximately 1% of Black Americans and produces a persistently undetectable haptoglobin in the absence of hemolysis.

Step 2: Peripheral Blood Smear - The Most Important Test

The peripheral blood smear is unquestionably the single most valuable test in the hemolytic anemia workup and should always be personally reviewed by the treating hematologist. Specific morphologic findings provide immediate diagnostic direction. Spherocytes suggest autoimmune hemolytic anemia, hereditary spherocytosis, burns, or Clostridium sepsis. Schistocytes (fragmented cells) point to thrombotic microangiopathies (TTP, HUS), DIC, mechanical heart valves, or HELLP syndrome. Sickle cells (drepanocytes) are diagnostic of sickle cell disease. Target cells are seen in thalassemia, hemoglobin C or E disease, liver disease, and the post-splenectomy state. Elliptocytes suggest hereditary elliptocytosis. Bite cells and blister cells are characteristic of oxidant hemolysis in G6PD deficiency. Acanthocytes (spur cells) are associated with liver disease, abetalipoproteinemia, and McLeod syndrome. Red cell agglutination on the room-temperature smear is the hallmark of cold agglutinin disease. Polychromasia reflects reticulocytosis. Basophilic stippling suggests lead poisoning, pyrimidine 5'-nucleotidase deficiency, or thalassemia.

Step 3: Direct Antiglobulin Test (DAT/Coombs)

The direct antiglobulin test (DAT) is the pivotal test for distinguishing immune-mediated from non-immune hemolysis. A positive DAT with IgG alone indicates warm AIHA. A positive DAT with C3d alone suggests cold agglutinin disease, paroxysmal cold hemoglobinuria (Donath-Landsteiner antibody), or some drug-induced causes. A DAT positive for both IgG and C3d is seen in warm AIHA with complement fixation or mixed AIHA. A negative DAT directs the workup toward non-immune causes including membrane disorders, enzyme deficiencies, hemoglobinopathies, mechanical hemolysis, and PNH. However, DAT-negative AIHA occurs in approximately 5 to 10% of AIHA cases, resulting from low-titer IgG, IgA-mediated hemolysis (not detected by standard polyspecific reagents), or low-affinity antibodies that dissociate during washing steps.

Step 4: Directed Testing Based on Pattern

Once the DAT result and smear morphology are known, testing becomes focused. If the DAT is positive, the workup proceeds along the AIHA pathway. If the DAT is negative and spherocytes are present, the evaluation targets hereditary spherocytosis with family history assessment, the eosin-5'-maleimide (EMA) binding test (a flow cytometry-based test that demonstrates reduced fluorescence in HS with 93% sensitivity and 99% specificity), and osmotic fragility testing. If the DAT is negative and bite cells or Heinz bodies are present, G6PD activity should be measured, with the important caveat that levels may be falsely normal during acute hemolysis when reticulocyte-rich blood is sampled (young red cells have higher enzyme activity). Retesting 2 to 3 months after the acute episode is essential. If the DAT is negative and schistocytes are prominent, a TMA workup including ADAMTS13 activity, complement studies, Shiga toxin testing, and pregnancy-related evaluation is indicated. When the DAT is negative and no specific morphologic clue is present, the differential broadens to include hemoglobin electrophoresis or HPLC, PNH flow cytometry (FLAER and CD59 analysis on both RBCs and WBCs), pyruvate kinase activity measurement, and workup for unstable hemoglobins using isopropanol and heat stability testing.

<image>A step-by-step diagnostic algorithm flowchart for hemolytic anemia workup. Begin with "Suspected Hemolysis" and first box: "Confirm with LDH, haptoglobin, indirect bilirubin, reticulocyte count." Second step: "Peripheral blood smear review" with branches for key morphologic findings: spherocytes, schistocytes, sickle cells, bite cells, agglutination, or nonspecific. Third step for each branch: specific tests. For spherocytes: DAT → if positive, AIHA workup; if negative, EMA binding test and osmotic fragility for HS. For schistocytes: ADAMTS13, complement, Shiga toxin for TMA. For bite cells: G6PD level and Heinz body prep. For sickle cells: hemoglobin electrophoresis. For agglutination: cold agglutinin titer, thermal amplitude. For nonspecific with negative DAT: PNH flow cytometry, PK activity, hemoglobin electrophoresis. Use decision diamonds and include specific test cutoff values. Clean clinical algorithm style with color-coded pathways.</image>

Membrane Disorders

Hereditary Spherocytosis (HS)

Hereditary spherocytosis is the most common hereditary hemolytic anemia in populations of Northern European descent, with a prevalence of approximately 1 in 2,000 to 5,000. Inheritance is autosomal dominant in 75% of cases, with the remainder being autosomal recessive or arising from de novo mutations. The underlying defect involves mutations in proteins of the red cell membrane skeletal complex, with ankyrin (ANK1) mutations being the most common (approximately 40%), followed by mutations in band 3 (SLC4A1), alpha- or beta-spectrin, and protein 4.2.

The clinical spectrum ranges from mild compensated hemolysis (hemoglobin above 11 g/dL) requiring no intervention to severe transfusion-dependent disease. Diagnosis relies on the identification of spherocytes on the peripheral smear, an elevated mean corpuscular hemoglobin concentration (MCHC above 36 g/dL, reflecting cellular dehydration as surface area is lost), and the EMA binding test, which has largely replaced osmotic fragility testing. Common complications include pigment gallstones from chronic bilirubin overproduction, aplastic crises triggered by parvovirus B19 infection (which temporarily halts erythropoiesis, removing the compensatory mechanism), and folate deficiency from increased erythropoietic demand. Treatment includes daily folic acid supplementation for all patients and splenectomy for moderate-to-severe disease, with subtotal splenectomy preferred in children to preserve some immune function. Cholecystectomy is performed for symptomatic gallstones.

Hereditary Elliptocytosis

Hereditary elliptocytosis results from mutations in spectrin or protein 4.1 and is usually mild or asymptomatic. Hereditary pyropoikilocytosis (HPP), seen in homozygous or compound heterozygous states, represents the severe end of the spectrum, with a characteristically very low MCV (50 to 60 fL) and marked red cell fragmentation.

Enzyme Deficiencies

G6PD Deficiency

G6PD deficiency is an X-linked enzymopathy affecting approximately 400 million people worldwide, making it the most common enzyme deficiency in humans. G6PD catalyzes the first step of the pentose phosphate pathway, generating NADPH, which is essential for maintaining reduced glutathione levels that protect the red cell against oxidative damage.

The WHO classification divides G6PD variants into classes based on residual enzyme activity. Class I variants (rare) cause chronic hemolysis. Class II variants (such as the Mediterranean variant) are severe with less than 10% residual activity. Class III variants (such as the A-minus variant common in African Americans) are moderate with 10 to 60% residual activity. Acute hemolytic crises are triggered by oxidative stressors, with infections being the most common precipitant, followed by drugs (primaquine, dapsone, rasburicase, sulfonamides, nitrofurantoin), fava beans, and metabolic acidosis including diabetic ketoacidosis.

During an acute crisis, intravascular hemolysis predominates, and the smear demonstrates characteristic bite cells (where Heinz bodies have been pitted out by splenic macrophages), blister cells, and hemoglobinuria. A critical diagnostic pitfall is that the G6PD level measured during reticulocytosis may be falsely normal because young red cells have higher enzyme activity than older cells. The diagnosis must be confirmed by retesting 2 to 3 months after the acute episode.

Pyruvate Kinase Deficiency

Pyruvate kinase (PK) deficiency is the most common glycolytic enzyme defect causing chronic hemolytic anemia and is inherited in an autosomal recessive pattern. Mutations in the PKLR gene reduce ATP production in red cells, leading to rigid, poorly deformable RBCs that undergo extravascular hemolysis. The peripheral smear characteristically shows echinocytes, and a paradoxical post-splenectomy reticulocytosis occurs because reticulocytes that were previously sequestered in the spleen are released into the circulation. Diagnosis requires PK enzyme activity measurement with molecular confirmation. Treatment has historically been supportive with folic acid, transfusions, and splenectomy (which provides a partial response), but mitapivat, a PKR activator, received FDA approval in 2024 as the first targeted therapy for PK deficiency, representing a landmark advance in the treatment of this disease.

Key Clinical Pearls

• The peripheral blood smear is the single most valuable test in the hemolytic anemia workup; always review it personally
• A negative DAT does not exclude immune hemolysis; ~5-10% of AIHA is DAT-negative
• Haptoglobin <10 mg/dL is highly specific for hemolysis; but remember it is an acute phase reactant (can be "normal" in hemolysis + inflammation) and congenitally absent in some individuals
• G6PD levels during acute hemolysis can be falsely reassuring; always recheck in the steady state
• Reticulocytopenic hemolysis (hemolysis without reticulocyte response) should prompt evaluation for concurrent B12/folate deficiency, parvovirus B19 infection, bone marrow infiltration, or autoimmune reticulocyte destruction
• LDH >1000 with low haptoglobin and elevated indirect bilirubin should prompt consideration of megaloblastic anemia (intramedullary hemolysis) in addition to true hemolysis

References

1. Barcellini W, Fattizzo B. Clinical Applications of Hemolytic Markers in the Differential Diagnosis and Management of Hemolytic Anemia. Dis Markers. 2015;2015:635670.
2. Phillips J, Henderson AC. Hemolytic Anemia: Evaluation and Differential Diagnosis. Am Fam Physician. 2018;98(6):354-361.
3. Bolton-Maggs PH, et al. Guidelines for the diagnosis and management of hereditary spherocytosis. Br J Haematol. 2012;156(1):37-49.
4. Grace RF, et al. Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. Blood. 2018;131(20):2183-2192.
5. Luzzatto L, et al. G6PD deficiency: a classic example of pharmacogenomics with on-going clinical implications. Br J Haematol. 2020;190(4):478-490.

Read this lecture as Markdown